REMARKS

Any fee that may be due in connection with this application may be charged to Deposit Account No. Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.

Claims 22-25, 28, 29, 31-33, 155-158, 164-168 and 170-172, 211, 212, 213, 216 and 217 are pending. Claim 211 indicating the amendment to conform to the restriction requirement is provided herein. A marked up copy of claim 211 showing the amendmentis appended hereto.

The Remarks filed in the previous responses are incorporated by reference. The Examiner has not issued a substantive Office Action since February 13, 2001. Typographical errors normally are not considered a basis on which to consider Response to be non-responsive. Generally such errors are noted in the next Office Action. A complete substantive response to the Office Action of February 13, 2001, was mailed on August 13, 2001.

* * *

In view of the above remarks and the amendments and remarks of record, consideration and allowance of the application are respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By: _____
Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24731-500B
Address all correspondence to:
HELLER EHRMAN WHITE & MCAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, CA 92122-9164
Telephone: 858 450-8400
Facsimile: 858 587-5360

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MICHEAL L. GRUENBERG

Serial No.: 08/700,565

Filed: July 25, 1996

For: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Art Unit: 1644

Examiner: Schwadron, R

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as First Class mail in an envelope addressed to:
Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202, on this date.

05/14/02
Date

Stephanie Seidman

MARKED UP CLAIMS (37 C.F.R. § 1.121)

Please amend claim 211 as follows:

211. (Amended) A method for generating immune cells for autologous cellular immunotherapy, comprising:

collecting leukocyte containing material from a mammal;

differentiating the leukocytes into Th1 [or Th2] cells;

and

exposing the [leukocyte containing] leukocyte-containing material to mitogenic monoclonal antibodies to induce *in vitro* cell proliferation sufficient for infusion into the mammal for use in an immunotherapy treatment, wherein the *in vitro* cell proliferation is produced without the use of exogenous interleukin-2.